NCT04074746View on ClinicalTrials.gov

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 18, 2020

Primary Completion Date

September 22, 2025

Study Completion Date

September 22, 2025

Conditions
Recurrent Anaplastic Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Classic Hodgkin LymphomaRecurrent Mycosis FungoidesRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Anaplastic Large Cell LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Classic Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
BIOLOGICAL

Anti-CD30/CD16A Monoclonal Antibody AFM13

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

DRUG

Fludarabine Phosphate

Given IV

BIOLOGICAL

Genetically Engineered Lymphocyte Therapy

Given AFM13-NK cells IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT04074746 - Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Biotech Hunter | Biotech Hunter